2003
An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine
Schoen RT, Deshefy-Longhi T, Van-Hoecke C, Buscarino C, Fikrig E. An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine. Clinical Therapeutics 2003, 25: 210-224. PMID: 12637121, DOI: 10.1016/s0149-2918(03)90027-0.Peer-Reviewed Original ResearchConceptsLyme disease vaccineFirst booster doseSecond booster doseBooster doseAdverse eventsBooster dosesPrimary seriesMonth 24Disease vaccineClinical trialsEfficacy trialsImmune responseIncidence of AEsPattern of AEsLyme diseaseMost adverse eventsGeometric mean titersTotal IgG antibodiesProportion of subjectsPositive test resultsSeroprotective levelsBooster vaccinationMonth 36Third vaccinationDiary cards
1998
Differential Expression of Borrelia burgdorferi Genes during Erythema Migrans and Lyme Arthritis
Fikrig E, Feng W, Aversa J, Schoen R, Flavell R. Differential Expression of Borrelia burgdorferi Genes during Erythema Migrans and Lyme Arthritis. The Journal Of Infectious Diseases 1998, 178: 1198-1201. PMID: 9806060, DOI: 10.1086/515684.Peer-Reviewed Original ResearchConceptsLyme arthritisLyme diseaseHuman infectionsPhase III clinical trialsMurine Lyme borreliosisRNA polymerase chain reactionErythema migrans biopsiesErythema migransProtective immunityClinical trialsVaccine candidatesTissue specimensLyme borreliosisPatientsGene expressionBorrelia burgdorferiDiseaseFirst direct demonstrationB. burgdorferiChain reactionArthritisInfectionBorrelia burgdorferi genesOspAB. burgdorferi gene expression
1995
Serologic responses of dogs naturally exposed to or vaccinated against Borrelia burgdorferi infection.
Barthold S, Levy S, Fikrig E, Bockenstedt L, Smith A. Serologic responses of dogs naturally exposed to or vaccinated against Borrelia burgdorferi infection. Journal Of The American Veterinary Medical Association 1995, 207: 1435-40. PMID: 7493871, DOI: 10.2460/javma.1995.207.11.1435.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, BacterialBacterial Outer Membrane ProteinsBacterial ProteinsBacterial VaccinesBiological AssayBlotting, WesternBorrelia burgdorferi GroupDog DiseasesDogsEnzyme-Linked Immunosorbent AssayFemaleImmune SeraImmunoglobulin GImmunoglobulin MLyme DiseaseMaleMiceMice, Inbred C3HVaccinationConceptsSerologic responseAntibiotic treatmentVaccinated dogsRecombinant outer surface proteinPassive protective activityBorrelia burgdorferi infectionMeans of ELISAImmunoblot analysisSeronegative dogsClinical responseSerologic testingClinical criteriaControl dogsAntibody responseMouse protectionB burgdorferiClinical trialsBurgdorferi infectionInfected dogsELISA titersProtective activityOuter surface proteinsUseful antigenDogsBorrelia burgdorferiProgress Towards a Vaccine for Lyme Disease
Telford S, Fikrig E. Progress Towards a Vaccine for Lyme Disease. BioDrugs 1995, 4: 49-60. DOI: 10.1007/bf03259070.Peer-Reviewed Original ResearchLyme diseaseLyme disease vaccineSurface protein AOuter surface protein AProtective immunityPrototype vaccineCareful surveillanceClinical trialsChronic natureDisease vaccineSuch vaccinesMouse modelVaccinated hostAdvanced stageVaccineDiseaseInfectious ticksInfectionAntibodiesProtein AYearsMiceImmunityTrials